Feb 29 |
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
|
Feb 27 |
SpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial Results
|
Feb 27 |
SpringWorks Therapeutics GAAP EPS of -$5.15 misses by $0.23, revenue of $5.45M
|
Feb 27 |
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
|
Feb 22 |
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
|
Feb 16 |
SpringWorks Therapeutics jumps amid takeover speculation
|
Feb 7 |
SpringWorks Therapeutics Inc Insider Sells Company Shares
|
Feb 6 |
SpringWorks Therapeutics Inc Chief People Officer Daniel Pichl Sells 26,181 Shares
|
Jan 31 |
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
|
Jan 8 |
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
|